Viral hepatitis

Ricardo Marrero, Eugene R Schiff

Research output: Contribution to journalArticle

Abstract

Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.

Original languageEnglish
Pages (from-to)330-333
Number of pages4
JournalCurrent Opinion in Gastroenterology
Volume18
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Hepatitis
Lamivudine
Interferons
Hepatitis A Vaccines
Ribavirin
Viral DNA
Chronic Hepatitis B
Chronic Hepatitis C
Gastroenterology
Chronic Hepatitis
Infection
Hepatitis B
Hepatitis B virus
Interferon-alpha
Half-Life
Therapeutics
Vaccines
Antigens
Liver
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Viral hepatitis. / Marrero, Ricardo; Schiff, Eugene R.

In: Current Opinion in Gastroenterology, Vol. 18, No. 3, 01.01.2002, p. 330-333.

Research output: Contribution to journalArticle

Marrero, Ricardo ; Schiff, Eugene R. / Viral hepatitis. In: Current Opinion in Gastroenterology. 2002 ; Vol. 18, No. 3. pp. 330-333.
@article{2db721bac8434f73ae37e4c9137650e8,
title = "Viral hepatitis",
abstract = "Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50{\%} of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.",
author = "Ricardo Marrero and Schiff, {Eugene R}",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00001574-200205000-00006",
language = "English",
volume = "18",
pages = "330--333",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Viral hepatitis

AU - Marrero, Ricardo

AU - Schiff, Eugene R

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.

AB - Viral hepatitis affects millions of people worldwide, making it one of the most important diseases in the field of hepatology. The response to the hepatitis A vaccine is optimal when targeted to patients with chronic hepatitis before development of hepatic decompensation. A new triple antigen vaccine for hepatitis B virus produces a greater degree of protection. Lamivudine can achieve a 3- to 4-log reduction in serum viral levels in patients with chronic hepatitis B infection. Lamivudine-resistant mutants appear in more than 50% of patients after prolonged treatment. Entecavir can be given safely for a short time and causes a pronounced reduction in hepatitis B viral DNA levels with slower rebound after stopping therapy than has been reported with lamivudine. Pegylated interferon has sustained absorption, a slower rate of clearance and a longer half-life than unmodified interferon alfa. Pegylated interferon alfa-2a administered once weekly is more effective than standard interferon alfa-2a administered three times weekly. In patients with chronic hepatitis C infection, the most effective therapy is the combination of pegylated interferon plus ribavirin. Other major advances in the field of viral hepatitis during the past year are highlighted.

UR - http://www.scopus.com/inward/record.url?scp=0036226708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036226708&partnerID=8YFLogxK

U2 - 10.1097/00001574-200205000-00006

DO - 10.1097/00001574-200205000-00006

M3 - Article

C2 - 17033303

AN - SCOPUS:0036226708

VL - 18

SP - 330

EP - 333

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -